Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.

PubWeight™: 1.40‹?› | Rank: Top 5%

🔗 View Article (PMID 15167584)

Published in Transplantation on May 15, 2004

Authors

Gudrun E Koehl1, Joachim Andrassy, Markus Guba, Sebastian Richter, Alexander Kroemer, Marcus N Scherer, Markus Steinbauer, Christian Graeb, Hans J Schlitt, Karl-Walter Jauch, Edward K Geissler

Author Affiliations

1: Department of Surgery, The University of Regensburg, Regensburg, Germany.

Articles citing this

Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66

Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett (2012) 2.05

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol (2008) 1.12

Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res (2008) 1.11

Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis. Arthritis Res Ther (2014) 1.10

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06

Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res (2009) 1.04

Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol (2008) 1.00

Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys (2011) 1.00

Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem (2010) 0.99

Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J (2015) 0.97

Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96

Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94

Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One (2011) 0.93

Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res (2015) 0.91

Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. Blood (2013) 0.90

Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother (2010) 0.90

Immunosuppression: towards a logical approach in liver transplantation. Clin Exp Immunol (2005) 0.88

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant (2012) 0.83

Management of recurrent hepatocellular carcinoma after liver transplant. World J Hepatol (2015) 0.81

Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81

Intrahepatic cholangiocarcinoma in a transplant liver--selective internal radiation therapy followed by right hemihepatectomy: report of a case. World J Surg Oncol (2014) 0.81

Growth hormone improves growth retardation induced by rapamycin without blocking its antiproliferative and antiangiogenic effects on rat growth plate. PLoS One (2012) 0.81

Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79

Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. PLoS One (2016) 0.78

Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs. Biochem Biophys Res Commun (2012) 0.78

Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77

Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro. Cancers (Basel) (2013) 0.77

Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol (2015) 0.76

Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management. World J Gastroenterol (2016) 0.75

Melanoma in organ transplant recipients: incidence, outcomes and management considerations. J Skin Cancer (2012) 0.75

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.75

Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation. Exp Ther Med (2015) 0.75

Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress. Mol Neurobiol (2016) 0.75

Articles by these authors

Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg (2012) 19.78

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell (2007) 14.87

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06

Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83

A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med (2006) 3.24

Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int (2012) 2.70

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64

OX40 costimulation turns off Foxp3+ Tregs. Blood (2007) 2.52

Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39

Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17

Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99

The German hospital malnutrition study. Clin Nutr (2006) 1.93

Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89

Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84

Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Crit Care Med (2007) 1.80

Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69

Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69

Endoscopic vacuum-assisted closure of anastomotic leakage following anterior resection of the rectum: a new method. Surg Endosc (2007) 1.68

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68

Developmental exposure to noninherited maternal antigens induces CD4+ T regulatory cells: relevance to mechanism of heart allograft tolerance. J Immunol (2007) 1.64

Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64

Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation (2006) 1.63

Intestinal ischemia: current treatment concepts. Langenbecks Arch Surg (2010) 1.60

Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant (2010) 1.59

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57

Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) (2009) 1.57

Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation. J Hepatol (2013) 1.56

Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of <3 months. Scand J Gastroenterol (2011) 1.55

Use of biosynthetic prosthesis (Omniflow II®) to replace infected infrainguinal prosthetic grafts--first results. Vasa (2012) 1.55

Quality of life and functional long-term outcome after partial pancreatoduodenectomy: pancreatogastrostomy versus pancreatojejunostomy. Ann Surg Oncol (2005) 1.52

IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51

Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLoS Pathog (2011) 1.51

Completion thyroidectomy: effect of timing on clinical complications and oncologic outcome in patients with differentiated thyroid cancer. World J Surg (2012) 1.50

Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44

Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43

Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant (2007) 1.43

High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42

The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41

Kidney transplant in children weighing less than 15 kg: donor selection and technical considerations. Transplantation (2002) 1.41

Pumpless extracorporeal interventional lung assist in patients with acute respiratory distress syndrome: a prospective pilot study. Crit Care (2009) 1.40

Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35

Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg (2005) 1.35

Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol (2009) 1.34

The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33

EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33

Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32

Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant (2008) 1.30

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res (2007) 1.30

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29

Surgical strategy in aortoesophageal fistulae: endovascular stentgrafts and in situ repair of the aorta with cryopreserved homografts. Ann Surg (2007) 1.29

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28

Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27

Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26

Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26

Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25

Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25

mTOR, cancer and transplantation. Am J Transplant (2008) 1.24

A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24

Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 1.22

Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22

Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med (2002) 1.22

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care (2009) 1.21

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20

Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19

GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19

The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg (2010) 1.18

Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18

Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17